Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249

Article  PubMed  Google Scholar 

Yuan S, Kar S, Carter P et al (2020) Is type 2 diabetes causally associated with cancer risk? Evidence from a two-sample mendelian randomization study. Diabetes 69(7):1588–1596

Article  PubMed  PubMed Central  Google Scholar 

Joh HK, Willett WC, Cho E (2011) Type 2 diabetes and the risk of renal cell cancer in women. Diabetes Care 34(7):1552–1556

Article  PubMed  PubMed Central  Google Scholar 

Tseng CH (2015) Type 2 Diabetes mellitus and kidney cancer risk: a retrospective cohort analysis of the National Health Insurance. PLoS ONE 10(11):e0142480

Article  PubMed  PubMed Central  Google Scholar 

Tang H, Shi W, Fu S et al (2018) Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med 7(4):1070–1080

Article  PubMed  PubMed Central  Google Scholar 

Garry EM, Buse JB, Gokhale M et al (2019) Study design choices for evaluating the comparative safety of diabetes medications: an evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes. Diabetes Obes Metab 21(9):2096–2106

Article  PubMed  PubMed Central  Google Scholar 

O'connor L, Bailey-Whyte M, Bhattacharya M et al. Association of metformin use and cancer incidence: a systematic review and meta-analysis. J Natl Cancer Inst. Published online January 30, 2024. https://doi.org/10.1093/jnci/djae021

Tseng CH (2016) Use of metformin and risk of kidney cancer in patients with type 2 diabetes. Eur J Cancer 52:19–25

Article  PubMed  Google Scholar 

Tseng CH (2014) Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. Eur J Cancer 50(16):2831–2837

Article  PubMed  Google Scholar 

Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54(8):2009–2015

Article  PubMed  Google Scholar 

Tseng CH (2012) Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 35(2):278–280

Article  PubMed  PubMed Central  Google Scholar 

Vallon V, Verma S (2021) Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 83:503–528

Article  PubMed  Google Scholar 

Burki TK (2012) FDA rejects novel diabetes drug over safety fears. Lancet 379(9815):507

Article  PubMed  Google Scholar 

Xu B, Kang B, Li S, Fan S, Zhou J. Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis. J Endocrinol Invest. Published online March 26, 2024. https://doi.org/10.1007/s40618-024-02351-0

Bogdanffy MS, Stachlewitz RF, van Tongeren S et al (2014) Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol 33(6):436–449

Article  PubMed  Google Scholar 

Phillips JA, Taub ME, Bogdanffy MS et al (2022) Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin. J Appl Toxicol 42(10):1570–1584

Article  PubMed  Google Scholar 

U.S. Food and Drug Administration. Questions and Answers on FDA’s Adverse Event Reporting System (FAERS). https://www.fda.gov/drugs/surveillance/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed 30 Jan 2024

Sarangdhar M, Tabar S, Schmidt C et al (2016) Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat Biotechnol 34(7):697–700

Article  PubMed  Google Scholar 

Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform 22(6):bbab347

Sung SY, Le TTH, Chen JH, Hsieh TF, Hsieh CL (2020) Alpha-1 blocker use increased risk of subsequent renal cell carcinoma: a nationwide population-based study in Taiwan. PLoS ONE 15(11):e0242429

Article  PubMed  PubMed Central  Google Scholar 

Spiazzi BF, Naibo RA, Wayerbacher LF et al (2023) Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110621

Article  PubMed  Google Scholar 

Ueda P, Svanström H, Hviid A et al (2022) Sodium-glucose cotransporter 2 inhibitors and risk of bladder and renal cancer: Scandinavian cohort study. Diabetes Care 45(5):e93–e96

Article  PubMed  PubMed Central  Google Scholar 

Koepsell H (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacol Ther 170:148–165

Article  Google Scholar 

Kuang H, Liao L, Chen H, Kang Q, Shu X, Wang Y (2017) Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma. Med Sci Monit 23:3737–3745

Article  PubMed  PubMed Central  Google Scholar 

Grempler R, Thomas L, Eckhardt M et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14(1):83–90

Article  Google Scholar 

Barocas DA, Rabbani F, Scherr DS, Vaughan ED Jr (2006) A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int 97(1):33–36

Article  PubMed  Google Scholar 

Tseng CH (2022) The effect of metformin on male reproductive function and prostate: an updated review. World J Mens Health 40(1):11–29

Article  PubMed  Google Scholar 

Tseng CH (2023) Effect of metformin on lower urinary tract symptoms in male patients with type 2 diabetes mellitus: a retrospective cohort study in Taiwan. World J Mens Health 41(3):680–691

Article  PubMed Central  Google Scholar 

Tseng CH (2022) Metformin’s effects on varicocele, erectile dysfunction, infertility and prostate-related diseases: a retrospective cohort study. Front Pharmacol 13:799290

Article  PubMed  PubMed Central  Google Scholar 

Tseng CH (2012) Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities? J Formos Med Assoc 111(3):123–131

Article  PubMed  Google Scholar